Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$25.74 +3.9%	$23.02	$13.40 ▼ $25.88	$4.34B	0.7	1.84 million shs	3.42 million shs
AKRO Akero Therapeutics	$49.23 +1.9%	$51.36	$21.34 ▼ $58.40	$3.94B	-0.28	1.06 million shs	802,546 shs
CYTK Cytokinetics	$38.34 +0.8%	$35.76	$29.31 ▼ $59.39	$4.59B	0.64	1.48 million shs	1.55 million shs
PHVS Pharvaris	$23.12 -1.0%	$20.27	$11.51 ▼ $26.33	$1.21B	-2.81	142,735 shs	53,502 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	0.00%	+1.62%	+11.67%	+17.11%	+61.58%
AKRO Akero Therapeutics	0.00%	-0.30%	-2.53%	+6.19%	+86.83%
CYTK Cytokinetics	0.00%	-0.85%	+2.76%	+25.54%	-32.24%
PHVS Pharvaris	0.00%	+3.68%	+15.31%	+44.59%	+29.96%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACAD ACADIA Pharmaceuticals	3.8507 of 5 stars	3.3	2.0	0.0	2.3	4.2	2.5
AKRO Akero Therapeutics	4.02 of 5 stars	3.5	2.0	4.7	3.6	0.8	0.0
CYTK Cytokinetics	3.7202 of 5 stars	3.5	1.0	4.6	3.2	0.8	0.0
PHVS Pharvaris	2.6368 of 5 stars	3.4	4.0	0.0	3.3	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.61	Moderate Buy	$28.88	12.18% Upside
AKRO Akero Therapeutics	3.00	Buy	$81.57	65.69% Upside
CYTK Cytokinetics	2.93	Moderate Buy	$71.58	86.71% Upside
PHVS Pharvaris	2.83	Moderate Buy	$35.60	53.98% Upside

Current Analyst Ratings Breakdown

Latest PHVS, ACAD, CYTK, and AKRO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	PHVS Pharvaris	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/13/2025	PHVS Pharvaris	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$55.00 ➝ $52.00
8/8/2025	ACAD ACADIA Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$32.00 ➝ $36.00
8/8/2025	CYTK Cytokinetics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $77.00
8/7/2025	ACAD ACADIA Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/7/2025	ACAD ACADIA Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sell ➝ Sell	$15.00 ➝ $17.00
8/7/2025	ACAD ACADIA Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$39.00 ➝ $40.00
8/7/2025	ACAD ACADIA Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$23.00 ➝ $24.00
8/7/2025	ACAD ACADIA Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$37.00 ➝ $38.00
8/4/2025	AKRO Akero Therapeutics	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
8/4/2025	AKRO Akero Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$76.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$957.80M	4.53	$0.70 per share	36.52	$4.87 per share	5.29
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	$12.82 per share	N/A
CYTK Cytokinetics	$18.47M	248.39	N/A	N/A	($3.08) per share	-12.45
PHVS Pharvaris	N/A	N/A	N/A	N/A	$4.00 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$226.45M	$1.33	19.35	33.87	6.55	21.80%	14.69%	9.41%	11/5/2025 (Estimated)
AKRO Akero Therapeutics	-$252.06M	-$2.00	N/A	N/A	N/A	N/A	-15.84%	-14.59%	N/A
CYTK Cytokinetics	-$589.53M	-$5.10	N/A	N/A	N/A	-707.17%	N/A	-45.52%	11/5/2025 (Estimated)
PHVS Pharvaris	-$145.24M	-$3.36	N/A	N/A	N/A	N/A	-69.09%	-63.34%	N/A

Latest PHVS, ACAD, CYTK, and AKRO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	PHVS Pharvaris	-$0.87	-$0.94	-$0.07	-$0.94	N/A	N/A
8/8/2025	Q2 2025	AKRO Akero Therapeutics	-$0.97	-$0.86	+$0.11	-$0.86	N/A	N/A
8/7/2025	Q2 2025	CYTK Cytokinetics	-$1.34	-$1.12	+$0.22	-$1.12	$1.95 million	$66.77 million
8/6/2025	Q2 2025	ACAD ACADIA Pharmaceuticals	$0.14	$0.16	+$0.02	$0.16	$263.07 million	$264.57 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	N/A
CYTK Cytokinetics	N/A	N/A	N/A	N/A	N/A
PHVS Pharvaris	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	2.91	2.83
AKRO Akero Therapeutics	0.02	12.66	12.66
CYTK Cytokinetics	N/A	6.76	6.76
PHVS Pharvaris	N/A	8.33	8.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
AKRO Akero Therapeutics	N/A
CYTK Cytokinetics	N/A
PHVS Pharvaris	N/A

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	26.50%
AKRO Akero Therapeutics	7.07%
CYTK Cytokinetics	2.70%
PHVS Pharvaris	11.84%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	168.71 million	124.00 million	Optionable
AKRO Akero Therapeutics	30	79.99 million	74.33 million	Optionable
CYTK Cytokinetics	250	119.66 million	116.43 million	Optionable
PHVS Pharvaris	30	52.29 million	46.10 million	Not Optionable

PHVS, ACAD, CYTK, and AKRO Headlines

Recent News About These Companies

Pharvaris (NASDAQ:PHVS) Upgraded to Hold at Zacks Research

August 22 at 9:58 AM | marketbeat.com

Pharvaris (NASDAQ:PHVS) Shares Up 6.2% - Here's What Happened

August 21 at 4:50 PM | marketbeat.com

Pharvaris (NASDAQ:PHVS) Upgraded at Zacks Research

August 21 at 2:00 AM | americanbankingnews.com

Pharvaris N.V. (NASDAQ:PHVS) Short Interest Update

August 20, 2025 | marketbeat.com

Pharvaris Advances Clinical Pipeline with Strong Financials

August 20, 2025 | msn.com

What is Leerink Partnrs' Estimate for Pharvaris Q3 Earnings?

August 19, 2025 | marketbeat.com

Q3 Earnings Estimate for Pharvaris Issued By Leerink Partnrs

August 19, 2025 | americanbankingnews.com

Cantor Fitzgerald Increases Earnings Estimates for Pharvaris

August 17, 2025 | marketbeat.com

Wedbush Comments on Pharvaris' Q3 Earnings (NASDAQ:PHVS)

August 17, 2025 | marketbeat.com

Cantor Fitzgerald Lifts Earnings Estimates for Pharvaris

August 17, 2025 | americanbankingnews.com

Wedbush Issues Positive Estimate for Pharvaris Earnings

August 17, 2025 | americanbankingnews.com

Wedbush Predicts Pharvaris' FY2029 Earnings (NASDAQ:PHVS)

August 16, 2025 | marketbeat.com

JMP Securities Cuts Pharvaris (NASDAQ:PHVS) Price Target to $52.00

August 16, 2025 | americanbankingnews.com

JMP Securities Lowers Pharvaris (NASDAQ:PHVS) Price Target to $52.00

August 15, 2025 | marketbeat.com

Pharvaris (NASDAQ:PHVS) Posts Quarterly Earnings Results, Misses Expectations By $0.07 EPS

August 14, 2025 | marketbeat.com

Pharvaris price target lowered to $52 from $55 at Citizens JMP

August 13, 2025 | msn.com

Pharvaris Reports Q2 2025 Financials and Advances Phase 3 Studies

August 12, 2025 | msn.com

Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update

August 12, 2025 | taiwannews.com.twT

Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update

August 12, 2025 | globenewswire.com

Pharvaris (PHVS) Projected to Post Earnings on Wednesday

August 6, 2025 | marketbeat.com

TD Asset Management Inc Has $1.23 Million Holdings in Pharvaris N.V. (NASDAQ:PHVS)

August 4, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHVS, ACAD, CYTK, and AKRO Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$25.74 +0.96 (+3.87%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$25.58 -0.15 (-0.60%)

As of 08/22/2025 07:24 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Akero Therapeutics NASDAQ:AKRO

$49.23 +0.94 (+1.95%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$49.03 -0.20 (-0.41%)

As of 08/22/2025 06:31 PM Eastern

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Cytokinetics NASDAQ:CYTK

$38.34 +0.29 (+0.76%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$38.34 0.00 (0.00%)

As of 08/22/2025 07:47 PM Eastern

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Pharvaris NASDAQ:PHVS

$23.12 -0.23 (-0.99%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$23.18 +0.05 (+0.24%)

As of 08/22/2025 04:10 PM Eastern

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time